Cationic Steroid Antimicrobial Compositions and Methods of Use

A method for treating a subject in need of treatment for human immunodeficiency virus (HIV) infection or pathogenesis, comprising administering a sufficient amount of cationic steroid antimicrobial (CSA) to treat the subject for the human immunodeficiency virus (HIV) infection or pathogenesis.

A method for decreasing susceptibility of a subject to a human immunodeficiency virus (HIV) infection or pathogenesis, comprising administering a sufficient amount of cationic steroid antimicrobial (CSA) to decrease susceptibility of the subject to human immunodeficiency virus (HIV) infection or pathogenesis.

A method for increasing or stabilizing numbers of CD4+ T cells in an HIV+ subject, comprising administering a sufficient amount of cationic steroid antimicrobial (CSA) to increase or stabilize numbers of CD4+ T cells in the HIV+ subject.

A method for decreasing or inhibiting HIV infection of a cell in vitro or in vivo, comprising administering a composition comprising a sufficient amount of cationic steroid antimicrobial (CSA) to inhibit HIV infection of the cell.

A method for providing a subject with protection against HIV infection or pathogenesis, comprising administering a sufficient amount of CSA-7, CSA-8, CSA-10, CSA-11, CSA-13, CSA-15, CSA-17, CSA-21, CSA-25, CSA-26, CSA-31, CSA-46, CSA-54 and CSA-59, as set forth in FIG. 10, to provide the subject with protection against the HIV infection or pathogenesis.

A method for treating a subject in need of treatment for an HIV infection or pathogenesis, comprising administering a sufficient amount of CSA-7, CSA-8, CSA-10, CSA-11, CSA-13, CSA-15, CSA-17, CSA-21, CSA-25, CSA-26, CSA-31, CSA-46, CSA-54 and CSA-59, as set forth in FIG. 10, to treat the subject for the HIV infection or pathogenesis.

A method for decreasing susceptibility of a subject to an HIV infection or pathogenesis, comprising administering a sufficient amount of CSA-7, CSA-8, CSA-10, CSA-11, CSA-13, CSA-15, CSA-17, CSA-21, CSA-25, CSA-26, CSA-31, CSA-46, CSA-54 and CSA-59, as set forth in FIG. 10, to decrease susceptibility of the subject to the HIV infection or pathogenesis.

A method for reducing, decreasing, inhibiting, ameliorating or preventing onset, severity, duration, progression, frequency or probability of one or more symptoms associated with HIV infection or pathogenesis in a subject, comprising administering a sufficient amount of CSA-7, CSA-8, CSA-10, CSA-11, CSA-13, CSA-15, CSA-17, CSA-21, CSA-25, CSA-26, CSA-31, CSA-46, CSA-54 and CSA-59, as set forth in FIG. 10, to decrease, inhibit, ameliorate or prevent onset, severity, duration, progression, frequency or probability of one or more symptoms associated with HIV infection or pathogenesis in the subject.

A method for identifying a candidate agent for treating a subject for an HIV infection or pathogenesis, comprising:

• a) providing a test agent, said test agent comprising a cationic steroid antimicrobial (CSA);
• b) contacting said test agent with HIV and ascertaining whether the test agent inhibits HIV infection or pathogenesis, wherein a test agent identified as inhibiting HIV infection or pathogenesis is a candidate agent for treating a subject for HIV infection or pathogenesis.

A method for identifying a candidate agent for decreasing susceptibility of a subject to an HIV infection or pathogenesis, comprising:

• a) providing a test agent, said test agent comprising a cationic steroid antimicrobial (CSA);
• b) contacting said test agent with HIV and ascertaining whether the test agent inhibits HIV infection or pathogenesis, wherein a test agent identified as inhibiting HIV infection or pathogenesis is a candidate agent for decreasing susceptibility of a subject to an HIV infection or pathogenesis.

A method for identifying a candidate agent for decreasing, inhibiting, ameliorating or preventing onset, severity, duration, progression, frequency or probability of one or more symptoms associated with HIV infection or pathogenesis, comprising:

• a) providing a test agent, said test agent comprising a cationic steroid antimicrobial (CSA);
• b) administering said test agent to a subject infected with or exposed to HIV and ascertaining whether the test agent decreases, inhibits, ameliorates or prevents onset, severity, duration, progression, frequency or probability of one or more symptoms associated with HIV infection or pathogenesis, wherein a test agent identified is a candidate agent for decreasing, inhibiting, ameliorating or preventing onset, severity, duration, progression, frequency or probability of one or more symptoms associated with HIV infection or pathogenesis.